vs
CENTRAL GARDEN & PET CO（CENT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是CENTRAL GARDEN & PET CO的1.0倍（$622.0M vs $617.4M），Royalty Pharma plc净利率更高（34.4% vs 1.1%，领先33.3%），Royalty Pharma plc同比增速更快（4.8% vs -6.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -17.2%）
Central Garden & Pet Co是总部位于美国的宠物用品及园艺产品供应商，主营宠物食品、护理用具、草坪养护用品、园艺配件等品类，产品通过大型商超、独立宠物店、园艺中心等渠道销往北美市场，旗下拥有多个行业知名消费品牌。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CENT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$617.4M
营收增速更快
RPRX
高出10.7%
-6.0%
净利率更高
RPRX
高出33.3%
1.1%
两年增速更快
RPRX
近两年复合增速
-17.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $617.4M | $622.0M |
| 净利润 | $6.8M | $214.2M |
| 毛利率 | 30.9% | — |
| 营业利润率 | 2.7% | 62.4% |
| 净利率 | 1.1% | 34.4% |
| 营收同比 | -6.0% | 4.8% |
| 净利润同比 | -51.2% | 2.9% |
| 每股收益（稀释后） | $0.11 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CENTRPRX
| Q4 25 | $617.4M | $622.0M | ||
| Q3 25 | $678.2M | $609.3M | ||
| Q2 25 | $960.9M | $578.7M | ||
| Q1 25 | $833.5M | $568.2M | ||
| Q4 24 | $656.4M | $593.6M | ||
| Q3 24 | $669.5M | $564.7M | ||
| Q2 24 | $996.3M | $537.3M | ||
| Q1 24 | $900.1M | $568.0M |
净利润CENTRPRX
| Q4 25 | $6.8M | $214.2M | ||
| Q3 25 | $-9.8M | $288.2M | ||
| Q2 25 | $95.0M | $30.2M | ||
| Q1 25 | $63.6M | $238.3M | ||
| Q4 24 | $14.0M | $208.2M | ||
| Q3 24 | $-34.2M | $544.0M | ||
| Q2 24 | $79.7M | $102.0M | ||
| Q1 24 | $62.0M | $4.8M |
毛利率CENTRPRX
| Q4 25 | 30.9% | — | ||
| Q3 25 | 29.0% | — | ||
| Q2 25 | 34.6% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 31.8% | — | ||
| Q1 24 | 31.0% | — |
营业利润率CENTRPRX
| Q4 25 | 2.7% | 62.4% | ||
| Q3 25 | -0.9% | 70.1% | ||
| Q2 25 | 14.1% | 36.3% | ||
| Q1 25 | 11.2% | 94.0% | ||
| Q4 24 | 4.3% | 60.9% | ||
| Q3 24 | -4.8% | — | ||
| Q2 24 | 11.6% | 50.2% | ||
| Q1 24 | 10.4% | -13.0% |
净利率CENTRPRX
| Q4 25 | 1.1% | 34.4% | ||
| Q3 25 | -1.4% | 47.3% | ||
| Q2 25 | 9.9% | 5.2% | ||
| Q1 25 | 7.6% | 41.9% | ||
| Q4 24 | 2.1% | 35.1% | ||
| Q3 24 | -5.1% | 96.3% | ||
| Q2 24 | 8.0% | 19.0% | ||
| Q1 24 | 6.9% | 0.8% |
每股收益（稀释后）CENTRPRX
| Q4 25 | $0.11 | $0.49 | ||
| Q3 25 | $-0.16 | $0.67 | ||
| Q2 25 | $1.52 | $0.07 | ||
| Q1 25 | $0.98 | $0.55 | ||
| Q4 24 | $0.21 | $0.46 | ||
| Q3 24 | $-0.51 | $1.21 | ||
| Q2 24 | $1.19 | $0.23 | ||
| Q1 24 | $0.93 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $721.1M | $618.7M |
| 总债务越低越好 | $1.2B | $9.0B |
| 股东权益账面价值 | $1.6B | $9.7B |
| 总资产 | $3.6B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.76× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CENTRPRX
| Q4 25 | $721.1M | $618.7M | ||
| Q3 25 | $882.5M | $938.9M | ||
| Q2 25 | $713.0M | $631.9M | ||
| Q1 25 | $516.7M | $1.1B | ||
| Q4 24 | $618.0M | $929.0M | ||
| Q3 24 | $753.5M | $950.1M | ||
| Q2 24 | $570.4M | $1.8B | ||
| Q1 24 | $301.3M | $843.0M |
总债务CENTRPRX
| Q4 25 | $1.2B | $9.0B | ||
| Q3 25 | $1.2B | $8.9B | ||
| Q2 25 | $1.2B | $8.0B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.6B | ||
| Q3 24 | $1.2B | $7.6B | ||
| Q2 24 | $1.2B | $7.6B | ||
| Q1 24 | $1.2B | $6.1B |
股东权益CENTRPRX
| Q4 25 | $1.6B | $9.7B | ||
| Q3 25 | $1.6B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.6B | $9.8B | ||
| Q1 24 | $1.5B | $9.9B |
总资产CENTRPRX
| Q4 25 | $3.6B | $19.6B | ||
| Q3 25 | $3.6B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.6B | $17.6B | ||
| Q4 24 | $3.5B | $18.2B | ||
| Q3 24 | $3.6B | $18.0B | ||
| Q2 24 | $3.6B | $17.7B | ||
| Q1 24 | $3.5B | $16.1B |
负债/权益比CENTRPRX
| Q4 25 | 0.76× | 0.92× | ||
| Q3 25 | 0.75× | 0.93× | ||
| Q2 25 | 0.75× | 0.84× | ||
| Q1 25 | 0.77× | 0.78× | ||
| Q4 24 | 0.78× | 0.74× | ||
| Q3 24 | 0.76× | 0.74× | ||
| Q2 24 | 0.75× | 0.78× | ||
| Q1 24 | 0.79× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-81.0M | — |
| 自由现金流率自由现金流/营收 | -13.1% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | -10.26× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $285.0M | — |
8季度趋势，按日历期对齐
经营现金流CENTRPRX
| Q4 25 | $-70.2M | $827.1M | ||
| Q3 25 | $182.7M | $702.6M | ||
| Q2 25 | $265.5M | $364.0M | ||
| Q1 25 | $-46.9M | $596.1M | ||
| Q4 24 | $-68.8M | $742.5M | ||
| Q3 24 | $203.1M | $703.6M | ||
| Q2 24 | $286.1M | $658.2M | ||
| Q1 24 | $-24.5M | $664.6M |
自由现金流CENTRPRX
| Q4 25 | $-81.0M | — | ||
| Q3 25 | $171.9M | — | ||
| Q2 25 | $251.7M | — | ||
| Q1 25 | $-57.5M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $193.0M | — | ||
| Q2 24 | $272.5M | — | ||
| Q1 24 | $-33.9M | — |
自由现金流率CENTRPRX
| Q4 25 | -13.1% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 26.2% | — | ||
| Q1 25 | -6.9% | — | ||
| Q4 24 | -11.4% | — | ||
| Q3 24 | 28.8% | — | ||
| Q2 24 | 27.3% | — | ||
| Q1 24 | -3.8% | — |
资本支出强度CENTRPRX
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.0% | — |
现金转化率CENTRPRX
| Q4 25 | -10.26× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 2.79× | 12.06× | ||
| Q1 25 | -0.74× | 2.50× | ||
| Q4 24 | -4.91× | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 3.59× | 6.45× | ||
| Q1 24 | -0.40× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CENT
| Garden Products Segment | $201.6M | 33% |
| Dogand Cat Products | $157.0M | 25% |
| Other Pet Products | $117.8M | 19% |
| Manufactured Product Other | $102.5M | 17% |
| Wild Bird Products | $38.5M | 6% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
